Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 20/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.80 |
| ▸ | PDE4A | P27815 | 9/20 | 0.76 |
| ▸ | PDE4B | Q07343 | 9/20 | 0.76 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.76 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6479748 | 1.00 | PDE4D (0.80) | PDE4DSLC6A2PDE4APDE4BPDE4C | |
| SCHEMBL6478487 | 0.99 | PDE4D (0.81) | PDE4DSLC6A2PDE4APDE4BPDE4C | |
| SCHEMBL6478214 | 0.99 | PDE4D (0.81) | PDE4DSLC6A2PDE4APDE4BPDE4C | |
| SCHEMBL6478218 | 0.99 | PDE4D (0.81) | PDE4DSLC6A2PDE4APDE4BPDE4C | |
| SCHEMBL6478491 | 0.99 | PDE4D (0.81) | PDE4DSLC6A2PDE4APDE4BPDE4C | |
| SCHEMBL7145709 | 0.90 | PDE4D (0.83) | PDE4DSLC6A2PDE4APDE4BPDE4C | |
| SCHEMBL7145708 | 0.90 | PDE4D (0.83) | PDE4DSLC6A2PDE4APDE4BPDE4C | |
| SCHEMBL6478371 | 0.90 | PDE4D (0.98) | PDE4DSLC6A2PDE4APDE4BPDE4C | |
| SCHEMBL7140287 | 0.90 | PDE4D (0.83) | PDE4DSLC6A2PDE4APDE4BPDE4C | |
| SCHEMBL6478369 | 0.90 | PDE4D (0.98) | PDE4DSLC6A2PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6933296-B2 | Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors | ALTANA PHARMA B.V. (NL) | 2005-08-23 | — | — | US | disclosed |
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ALTANA PHARMA B.V. (NL) | 2003-10-16 | — | — | US | disclosed |
| EP-1296956-A1 | COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS | ALTANA Pharma AG (DE) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001094319-A1 | COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS | ALTANA PHARMA AG (DE) | 2001-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195215-A1 | Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors | ADRB1, ADRB2, ADRA1D | PDE4D 19/4885SLC6A2 890/4885PDE4A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.